Search results
Results From The WOW.Com Content Network
Shares of Cassava Sciences (NASDAQ: SAVA) were 5.3% lower as of 11:05 a.m. ET on Monday after falling as much as 19% earlier in the morning. The decline came on the heels of the federal indictment ...
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $39.08, marking a -0.13% move from the previous day.
After Wang's June 2024 indictment, the stock fell by 46% to a new low of about $10 per share. [19] [26] Following the November 2024 announcement that simufilam had failed its Phase III trials, Cassava stock fell to $4.29 per share, losing 84% of its value in one day. [27] [28]
Many investors had enough of the company and sold off its stock to the point where it lost nearly 11% of its value across the Friday trading session. That was a far steeper fall than the 0.2% sag ...
Cassava Sciences, Inc. (SAVA) closed at $47.17 in the latest trading session, marking a -1.34% move from the prior day. Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should ...
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $26.43, marking a -1.38% move from the previous day.
Cassava Sciences (NASDAQ:SAVA) stands to gain a good deal this year. This will all depend on the company’s Phase 3 clinical trials progress in the results on actual patients with Alzheimer’s ...
Alzheimer’s disease (AD) is a notoriously difficult condition to treat. In fact, there are currently no available drugs that can halt the advancement of the memory-destroying disease. Finding a ...